Robert S. Coleman

Robert S. Coleman is a professor of chemistry at Ohio State University. He has been a member of the faculty in the Department of Chemistry since 1996, having moved to Ohio State as an Associate Professor from the University of South Carolina, after seven years at that institution. He was promoted to Full Professor in 2000. Professor Coleman is nationally and internationally recognized as a leading practitioner in the field of synthetic organic and medicinal chemistry, and as an invaluable collaborator in a number of highly successful multidisciplinary research programs. He received his Ph.D. degree working with Professor Dale L. Boger (then at Purdue), completing the first total synthesis of the antitumor agent CC-1065 (J. Am. Chem. Soc. 1988, 10, 1321). He was subsequently an NIH postdoctoral fellow at Yale University with Professor Samuel J. Danishefsky, where he completed (with M. Paz Cabal), the first total synthesis of the aglycone of the antitumor agent calicheamicin (J. Am. Chem. Soc. 1990, "112", 3253).

Professor Coleman's independent research contributions include:

Accomplished the first total chemical synthesis of the novel antitumor agent Azinomycin A ("Angew. Chem., Int. Ed." 2001, "40", 1736).

Developed the first synthesis of DNA containing sulfur-bearing nucleosides ("J. Am. Chem. Soc." 1992, "114", 9229).

Developed the first stereocontrolled total synthesis of the kinase inhibitor Calphostin A ("J. Am. Chem. Soc." 1995, "117", 10889).

Developed the first computer generated model of an Azinomycin B/DNA Cross-Link ("J. Med. Chem." 2002, "45", 861).

Developed the first fluorescent probe for studying ultrafast DNA dynamics ("J. Org. Chem." 1998, "63", 5700).

Published the first comprehensive study of the DNA binding properties of Azinomycin B ("J. Am. Chem. Soc." 2002, "124", 13008).

Developed a novel hetero-bis-metallated butadiene for the synthesis of polyene natural products ("Org. Lett." 2005, "7", 2289), including the first total synthesis of the antitumor agent lucilactaene ("J. Am. Chem. Soc." 2005, "127", 16038) and 2'-O-methylmyxalamide D ("J. Am. Chem. Soc." 2007, "129", 3826).

Professor Coleman has been an invited speaker at numerous scientific conferences, including several international conferences. He has been invited to visit most major pharmaceutical companies to present his research, including Merck, Pfizer, Glaxo, Lilly, Schering-Plough, Wyeth-Ayerst, Bristol-Myers Squibb, Amgen, Sepracor, and Genentech.

Professor Coleman has received a number of awards for research. He held an NIH postdoctoral fellowship at Yale, and was a Dreyfus Foundation Distinguished New Faculty Awardee (1989-1994), an American Cancer Society Junior Faculty Research Awardee (1991-1993), and a Sloan Foundation Research Fellow (1995-1998). In addition, he has won teaching awards at both University of South Carolina and Ohio State University (Alumni Distinguished Teaching Award, 1998). Professor Coleman has a diverse publication record within the general field of synthetic organic and medicinal chemistry. He has nearly 100 publications to his credit, and he has been a major recipient of federal and private funding, having received more than $5.8M during the course of his independent career. The National Cancer Institute has funded his research program continuously since 1994.

Professor Coleman is currently Vice Chair for Graduate Studies in the Department of Chemistry at Ohio State.

External links

* [http://www.chemistry.ohio-state.edu/~coleman/ Coleman Research Group]